• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » MCRA touts aid to Vertiflex in Superion PMA

MCRA touts aid to Vertiflex in Superion PMA

June 26, 2015 By Fink Densford

MCRA touts aid to Vertiflex in Superion PMAMusculoskeletal Clinical Regulatory Advisers said Wednesday it aided VertiFlex in winning pre-market approval from the FDA for its Superion interspinous spacer.

The neuro-musculoskeletal and orthopedic advising and research organization said its assistance to Vertiflex helped reduce the average 26-month PMA review period to only 14 months.

The Superion approval, won in May, marks the 1st spinal device to go to an FDA panel meeting and receive a PMA approval since 2007 with the last 4 failing to receive a favorable FDA decision, MCRA said.

“In the changing spinal landscape of minimally invasive surgical options, the level-one evidence of the Superion is an achievement for everyone at VertiFlex. We are very happy with our decision to entrust the MCRA team with assisting us in this important phase of our company. We could not be more impressed with MCRA’s ability to understand our technology and the volumes of supporting clinical data while working hand-in-hand with VertiFlex to achieve this important regulatory milestone,” Vertiflex CEO Earl Fender said in prepared remarks.

“MCRA’s integrated team of regulatory, clinical, reimbursement, and quality assurance leaders allows for us to assist clients in a holistic manner that today’s complexities require for achieving success. We are extremely pleased to have had the opportunity to advise and counsel VertiFlex through the FDA’s rigorous PMA process enabling them to provide U.S. patients with a proven, advanced technology,” MCRA general manager David Lown said in a press release.

The approval followed an FDA advisory panel recommendation in February that the device be approved, based on data from a 470-patient trial that showed a greater than 80% clinical success rate at 24 months.

VertiFlex won CE Mark approval for the Superion in the European Union in 2007.

Filed Under: Business/Financial News, Regulatory/Compliance, Spine Tagged With: Musculoskeletal Clinical Regulatory Advisers, VertiFlex Inc.

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy